How Much Disease Remains After Ovarian Cancer Treatment? Small IMNN-001 Trial Releases Early Signals

Even when ovarian cancer appears to have subsided after surgery and drug treatment, a small number of residual cancer cells may still become the seeds of future recurrence. A small clinical study led by The University of Texas MD Anderson Cancer Center is now using second-look laparoscopy and tumor DNA in the blood to identify early whether the experimental therapy IMNN-001 can help frontline treatment achieve more thorough clearance.

This randomized, open-label, multicenter Phase 1/2 study, registered as NCT05739981, is expected to enroll 30 patients with newly diagnosed advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Both groups receive carboplatin, paclitaxel, and bevacizumab; the experimental group also receives weekly intraperitoneal IMNN-001. After patients complete interval debulking surgery and subsequent treatment, they undergo second-look laparoscopy to look for microscopic residual disease that imaging or routine assessments may have missed.

Nine patients in each group have currently reached this assessment point. Preliminary data released by IMUNON show that microscopic residual disease was still detected in 44% of the IMNN-001 group, compared with 67% of the control group; circulating tumor DNA clearance rates were 87.5% and 62.5%, respectively. The company also said that the proportion with “no evidence of disease” after completing frontline treatment was 100% versus 56%. These differences point in a consistent direction, but with only 18 evaluable patients overall, a small number of cases is enough to substantially change the percentages, and the data cannot currently establish that the therapy is effective.

The central concept behind IMNN-001 is to package plasmid DNA encoding interleukin-12 (IL-12) in a nanodelivery system and deliver it directly into the abdominal cavity, so that the treatment-related protein is expressed primarily in the area where the tumor is located. IL-12 can activate T cells, natural killer cells, and other antitumor immune responses, but systemic inflammatory toxicity has previously limited its clinical development; local administration aims to activate the immune environment in the abdominal cavity while reducing systemic exposure.

The company said that, as of this data cutoff, no cytokine release syndrome, systemic toxicity, or serious immune-related adverse events had been observed in the study. However, this is an interim safety summary released by the company, and both the number of participants and the follow-up duration are limited, making it insufficient to declare that the historical safety barriers associated with IL-12 have been overcome. ClinicalTrials.gov had also not posted formal study results as of its June 2026 update, so the full frequencies of adverse events, statistical analyses, and the number of evaluable patients for each biomarker remain to be disclosed.

Microscopic residual disease and circulating tumor DNA can provide earlier indications of treatment response than conventional imaging, but they remain surrogate or exploratory measures. The questions that truly matter to patients are whether recurrence is delayed and whether progression-free survival and overall survival improve. This study will assess progression-free survival as a secondary endpoint, while IMNN-001 has also entered the Phase 3 OVATION 3 trial. Only if the current signals can be replicated in a larger population and improvements in biomarkers are shown to correspond to longer disease control could the frontline treatment landscape for advanced ovarian cancer potentially change.